Business Context and Reporting Period
This Form 8-K Current Report was filed by Bruker BioSciences Corporation on September 27, 2004. The filing discloses the entry into a material definitive agreement and the appointment of a new principal officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on executive compensation terms.
- New CFO Annual Salary: $225,000
- Annual Cash Bonus Eligibility: Up to $60,000
- Initial Stock Option Grant: 125,000 shares
- Option Exercise Price: Nasdaq closing price on October 25, 2004
- Option Term: 10 years
- Vesting Schedule: 20% annually over five years
Material Changes
The primary material change is the appointment of William J. Knight as Chief Financial Officer, effective October 25, 2004. Mr. Knight will serve as the Company's principal financial officer and principal accounting officer. He previously served as CFO for Anika Therapeutics, Inc. (2002-2004), Zycos, Inc. (2000-2002), and NMT Medical, Inc. (1998-2000).
Outlook, Risks, and Unusual Items
The filing does not contain management commentary on financial outlook, risks, or contingencies. It notes that Mr. Knight is eligible for future annual stock option grants of 25,000 shares in 2005 and 50,000 shares in subsequent years, subject to Compensation Committee approval.
Investor Verification Checklist
- Confirm the effective start date of William J. Knight as CFO (October 25, 2004).
- Verify the Nasdaq closing price on October 25, 2004, to determine the exercise price of the 125,000 share option grant.
- Review the attached Employment Offer Letter (Exhibit 10.25) for additional benefit details not summarized in the text.
- Monitor future filings for the Compensation Committee's approval of the 2005 and subsequent annual stock option grants.